Treatment with the PPAR&#945; agonist fenofibrate improves the efficacy of CD8<sup>+</sup> T cell therapy for melanoma.

Hasanpourghadi, Mohadeseh; Chekaoui, Arezki; Kurian, Sophia; Kurupati, Raj; Ambrose, Robert; Giles-Davis, Wynetta; Saha, Amara; Xiaowei, Xu; Ertl, Hildegund C J

Treatment with the PPARα agonist fenofibrate improves the efficacy of CD8⁺ T cell therapy for melanoma.

Hasanpourghadi, Mohadeseh; Chekaoui, Arezki; Kurian, Sophia; Kurupati, Raj; Ambrose, Robert; Giles-Davis, Wynetta; Saha, Amara; Xiaowei, Xu; Ertl, Hildegund C J.

Afiliação

Hasanpourghadi M; The Wistar Institute, Philadelphia, PA 19104, USA.
Chekaoui A; The Wistar Institute, Philadelphia, PA 19104, USA.
Kurian S; The Wistar Institute, Philadelphia, PA 19104, USA.
Kurupati R; The Wistar Institute, Philadelphia, PA 19104, USA.
Ambrose R; The Janssen Pharmaceutical Companies of Johnson & Johnson, New Brunswick, NJ, USA.
Giles-Davis W; The Wistar Institute, Philadelphia, PA 19104, USA.
Saha A; The Wistar Institute, Philadelphia, PA 19104, USA.
Xiaowei X; The Wistar Institute, Philadelphia, PA 19104, USA.
Ertl HCJ; Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.